Evotec Proposes Dieter Weinand as New Supervisory Board Chairman

Evotec SE has nominated Dieter Weinand as Chairman of its Supervisory Board, with the proposal set for a vote at the upcoming Annual General Meeting on June 11, 2026. Dieter Weinand, an industry leader with over 30 years in the pharmaceutical sector, is expected to bring a wealth of experience to the role. The nomination underscores Evotec's focus on enhancing commercial execution, strategic partnerships, and profitability.

Weinand is poised to succeed Prof. Dr. Iris Löw-Friedrich, who concludes her term in 2026, reflecting a planned leadership transition. CEO Dr. Christian Wojczewski praised Weinand’s commercial expertise and governance experience. Weinand, having held senior roles at major pharmaceutical companies like Bayer and Pfizer, intends to prioritize supporting Evotec’s strategic priorities and strengthening its collaborations.